Auric,
It's already acknowledged that today's news was minor, though slightly positive. Certainly the data submitted on the first go-round was poor, but that had to do with qualifying/characterizing the control group (polyp counts in the colon). My understanding is that issue is resolved, and the efficacy of the drug is not in that much doubt. Give me a link that'll show me otherwise and I'll sell at 3, just as you ask, (or if I'm convinced before the herd, maybe I'll be able to sell to someone else at a slightly higher price).
BTW, the conference call on the data was on June 16, 1999, and there's no point in another one at this time, or for supplemental data:
biotechclinician.com
Absolutely agree the game is far from over.
Cheers, Tuck |
